Analyst Price Target is $6.60
▲ +186.96% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for Taysha Gene Therapies in the last 3 months. The average price target is $6.60, with a high forecast of $8.00 and a low forecast of $5.00. The average price target represents a 186.96% upside from the last price of $2.30.
Current Consensus is
Buy
The current consensus among 10 contributing investment analysts is to buy stock in Taysha Gene Therapies. This Buy consensus rating has held steady for over two years.
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Read More